XBRU
AGFB
Market cap74mUSD
Jul 10, Last price
0.41EUR
1D
-1.90%
1Q
-15.92%
Jan 2017
-88.77%
Name
AGFA Gevaert NV
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Agfa-Gevaert NV develops, manufactures, and markets various analog and digital systems worldwide. It operates through four segments: HealthCare IT, Digital Print and Chemicals, Radiology Solutions, and Contractor Operations and Services (CONOPS). The Healthcare IT segment provides healthcare's enterprise imaging platform. The Digital Print & Chemicals segment offers printers, inks, and software for sign and display and packaging printing companies; inkjet inks and fluids for various industrial inkjet applications, such as signs, displays, billboards, promotional materials, packaging, leather goods, laminated flooring, and decorative materials, as well as for printed electronics industry; electrolysis membranes to the hydrogen production industry; and printable synthetic papers and films for graphics, non-destructive testing, aerial photography, and printed circuit board production. The Radiology Solutions segment provides analog and digital imaging technology for diagnostic imaging market to meet the needs of specialized clinicians in hospitals and imaging centers; and X-ray film, hardcopy film and printers, digital radiography equipment, and image processing software. This segment also offers SmartXR that provides radiographers with predictive workflow assistance which includes digital radiography tools for dose, alignment, patient positioning, image rotation, and others. The CONOPS segment engages in supply of film and chemicals, as well support services. It sells its products through its own sales organization, as well as through a network of agents and representatives. Agfa-Gevaert NV was founded in 1867 and is headquartered in Mortsel, Belgium.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||